In a report released on November 24, Ritu Baral from TD Cowen maintained a Buy rating on Inventiva, with a price target of €10.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ritu Baral has given his Buy rating due to a combination of factors surrounding Inventiva’s ongoing clinical trials and financial position. The company’s Phase 3 NATIV3 MASH trial, which is fully enrolled, is expected to yield promising results in the second half of 2026. The trial’s design, which includes a diverse patient cohort and a robust primary endpoint focusing on both fibrosis and MASH resolution, supports optimism regarding its potential success.
Additionally, Inventiva’s financial health is bolstered by a strong cash position, with €97.6 million at the end of the third quarter of 2025 and an anticipated €139 million from a recent US public offering. This financial stability, along with an expected €116 million from a structured financing deal, ensures operational expenses are covered until the first quarter of 2027. These factors collectively contribute to the positive outlook and Buy rating for Inventiva’s stock.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of 0RNK in relation to earlier this year.